DEBATE: Sequencing Small Molecules Is the Way ... - CLL Support
DEBATE: Sequencing Small Molecules Is the Way to Go, by Dr. Jennifer R.Brown at the Society of Hematologic Oncology 2022 Annual Meeting
You need to be a member of this community to see this post.
Read more about...
2 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success
I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies
Patients discontinue BTKi's due to resistance and intolerance. We evaluated the safety and efficacy...
Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor. (BRUIN CLL-321 Phase III trial results reported at ASH2024)
Pirtobrutinib is the first FDA approved non-covalent BTK inhibitor (BTKi) for the treatment of CLL....
BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'
In just a short time, in many places, BTK inhibitors (BTKi) have largely replaced...
Advances in Targeted Therapy for R/R CLL OncLive videos & transcripts by Nirav Shah MD & Nicole Lamanna MD
Advances in Targeted Therapy for R/R CLL
(These OncLive presentations are intended for medical...
Related Posts
- Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
- Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
Unmutated patients on venetoclax?
ASH 2019 CLL highlights and 'hot' topics - Drs Nicole Lamanna & Florence Cymbalista- Real-World Study Shows Limited Implementation of Reccomended Biomarker Testing in CLL
